PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-7.43
Negative P/E while AGEN shows 1.82. Joel Greenblatt would examine path to profitability versus competitor.
819.05
P/S above 1.5x AGEN's 5.15. Michael Burry would check for mean reversion risks.
2.38
P/B less than half of AGEN's 31.10. David Dodd would verify if asset quality justifies this discount.
-33.74
Negative FCF while AGEN shows P/FCF of 11.94. Joel Greenblatt would examine cash flow improvement potential.
-34.15
Negative operating cash flow while AGEN shows P/OCF of 9.91. Joel Greenblatt would examine operational improvement potential.
2.38
Fair value ratio less than half of AGEN's 31.10. David Dodd would verify if competitive position justifies this discount.
-3.37%
Negative earnings while AGEN shows yield of 13.72%. Joel Greenblatt would examine path to profitability.
-2.96%
Negative FCF while AGEN shows yield of 8.37%. Joel Greenblatt would examine cash flow improvement potential.